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Background: Genome-wide association studies have been successful in identifying common genetic variants for
human diseases. However, much of the heritable variation associated with diseases such as Parkinson’s disease
remains unknown suggesting that many more risk loci are yet to be identified. Rare variants have become
important in disease association studies for explaining missing heritability. Methods for detecting this type of
association require prior knowledge on candidate genes and combining variants within the region. These methods
may suffer from power loss in situations with many neutral variants or causal variants with opposite effects.
Results: We propose a method capable of scanning genetic variants to identify the region most likely harbouring
disease gene with rare and/or common causal variants. Our method assigns a score at each individual variant
based on our scoring system. It uses aggregate scores to identify the region with disease association. We evaluate
performance by simulation based on 1000 Genomes sequencing data and compare with three commonly used
methods. We use a Parkinson’s disease case–control dataset as a model to demonstrate the application of our
method.
Our method has better power than CMC and WSS and similar power to SKAT-O with well-controlled type I error
under simulation based on 1000 Genomes sequencing data. In real data analysis, we confirm the association of
α-synuclein gene (SNCA) with Parkinson’s disease (p = 0.005). We further identify association with hyaluronan synthase
2 (HAS2, p = 0.028) and kringle containing transmembrane protein 1 (KREMEN1, p = 0.006). KREMEN1 is associated
with Wnt signalling pathway which has been shown to play an important role for neurodegeneration in Parkinson’s
disease.
Conclusions: Our method is time efficient and less sensitive to inclusion of neutral variants and direction effect of
causal variants. It can narrow down a genomic region or a chromosome to a disease associated region. Using
Parkinson’s disease as a model, our method not only confirms association for a known gene but also identifies two
genes previously found by other studies. In spite of many existing methods, we conclude that our method serves
as an efficient alternative for exploring genomic data containing both rare and common variants.
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Genome-wide association studies (GWAS) have been suc-
cessful in identifying common genetic variants underlying
human diseases and complex phenotypes [1]. For most
traits, however, the sum of the identified genetic effects
generally comprises less than half of the estimated trait her-
itability [2]. For Parkinson’s disease, studies have shown that
the genetic variance identified by top GWAS hits alone is
between 3% to 5% and it is about 27% by meta-analysis [3].
Possible explanations for the missing heritability include
low-frequency polymorphisms or rare variants that are not
captured by genotyping platforms and undetected small
effects from different loci that may together comprise a sig-
nificant contribution to heritability [4,5]. Recent advances
in next generation sequencing technology have made gen-
etic variants over a wider frequency spectrum available for
disease association studies. With efforts from the 1000
Genomes Project (TGP) which sought to identify most rare
genetic variants in a group of 1092 multi-ethnic individuals,
a new generation of GWAS is being designed to enable the
discovery of lower frequency genetic variants by using next
generation sequencing data [6,7].
Rare variants, here defined as genetic variants with
minor allele frequencies (MAFs) less than 1%, can play
an important role in the etiology of complex traits [8].
Traditional single-variant test focuses on the marginal
effect on disease by analyzing markers one at a time.
The power of this type of test is low for rare variant as-
sociation due to the inherent low frequency and large
number of rare variants in the genome [9,10] particularly
in large scale data such as sequencing based association
studies. It has been suggested that pooling minor alleles
at rare variants into a measure of burden at a locus can
help enrich association signals and mitigate the power
loss due to allelic heterogeneity and high dimensionality
[11]. Pooling based on either collapsing rare variants
into a single indicator of the presence of any minor al-
leles or summing weighted minor allele counts over rare
and/or common variants has been the earliest proposal
for detecting rare variant association [12]. For instance, the
Combined Multivariate and Collapsing (CMC) method
and the Weighted Sum Statistic (WSS) method have been
shown to be superior to single-variant test statistics [13].
CMC collapses genotypes across all variants into an indica-
tor variable such that an individual is coded as 1 if a rare
allele as defined by the pre-specified MAF threshold is
present at any of the variant sites, and as 0 otherwise,
followed by a multivariate test such as Hotelling’s T2 test
[14]. WSS uses a non-parametric sum test in which each
mutation is weighted according to its count in control sub-
jects and then permutes the disease phenotype to assess
the significance of a Wilcoxon-type test statistic [15].
In the case when neutral variants are included, as is
likely to be so in sequencing based association datawhere most variants are expected to have little or no ef-
fect, pooling tests lose power. Such tests lose power espe-
cially when the extent of negative linkage disequilibrium
(i.e., D < 0) between neutral and risk variants is large
thereby causing masking of the true disease association
attributed to rare variant effect [16]. The inclusion of pro-
tective variants whose effects are in the opposite direction
from risk variants will further exacerbate the masking ef-
fect and power loss in finding the susceptibility gene [17].
Excluding variants based on prior information such as an-
notation and functional predictions may improve the per-
formance of pooling tests, however, it may result in loss of
information due to bias in prior knowledge [18].
To circumvent the masking effect of non-causal and
protective variants, alternative methods have been de-
vised using approaches such as model selection, adaptive
MAF thresholds and/or weighting schemes to determine
how and which variants to collapse in order to improve
power [12,19-27]. An example is the variable-threshold
method which assumes that the effects of the combined
rare mutations on the phenotype are in the same direc-
tion. It uses the maximum of the test statistics over all
allele frequency thresholds to assess statistical signifi-
cance by permutation [21]. To detect both deleterious
and protective effects, several methods such as adaptive
sum test and burden or mutation position test have in-
corporated the signs of the observed effects into the bur-
den test statistics [22,23].
Sums of single-variant test statistics have previously
been shown to be powerful for joint inference in associ-
ation studies [24-26]. Multi-variant and gene- or region-
based methods that make joint inference based on
single-variant test statistics consider only the magnitude
of deviation from the expected null distribution. These
type of methods are inherently robust to the inclusion of
neutral and protective variants [13,28]. A recent study
has pointed out that rare variant association tests (e.g.,
SKAT) that are robust to the inclusion of neutral and
protective variants have actually arrived at procedures
similar to performing region-wise inference using single-
variant test statistics [16,27,29,30]. This type of tests pro-
vides an overall result without identifying the region
with disease association.
In this study, we propose a method that is capable of
scanning genetic variants and identifies the sub-sequence
with disease association. Our method utilizes single-
variant association tests to generate single-variant scores
at each individual marker and rather than summing the
test statistics, we sum the single-variant scores derived by
our scoring system to generate the partial sum scores
along the sequence. To reduce dimensionality which has
been a challenging problem with large-scale data such as
in sequencing-based association studies, our method uses
a partitioning procedure to divide the sequence into sub-
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identification of the disease gene by permutation. We com-
pare our method to the two originally proposed pooling
tests (i.e., CMC [14] and WSS [15]) and the optimal test of
SKAT, namely, SKAT-O [29], under several simulation sce-
narios. The simulation datasets have been generated based
on sequencing data of the European reference panel from
TGP [6]. Using Parkinson’s disease as a model, we demon-
strate the application of our method by analyzing a real
case–control dataset for Parkinson’s disease [31].
Methods
General maximal segmental score (GMSS)
Our method is based on a more general class of max-
imal segmental scores (GMSS), with the conventional
maximal segmental scores (MSS) as its special case [32].
The MSS has wide applications on measuring the se-
quence similarity and has been implemented in algo-
rithms such as the Basic Local Alignment Search Tool
(BLAST) [33,34]. When comparing two amino acid
query sequences based on pairs of corresponding nucle-
otides, BLAST often uses a discrete score system by
scoring a matched pair with 1, a non-matched with −1,
and gaps (insertion or deletion) with certain negative
values as penalty [34].
In this study which aims to locate the disease gene,
the idea of GMSS is to identify a region with the stron-
gest “composite” signal of case–control difference. The
significance of the difference is measured by the p-value
from each marker within the region. Different from the
discrete nature of matching-vs.-non-matching status for
nucleotide or protein pairs considered in BLAST, the p-
values here are continuous. Thus, to be able to derive
the asymptotic distribution of the maximal segmental
scores for testing purpose, our pervious methods categorize
the p-values into discrete scores by using scoring systems
similar to those used in BLAST [35,36]. However, if a
complete case–control data set and efficient computation
capacity are available, using a more general continuous
score is plausible. We propose to use a different scoring
system with continuous scores in this study and the scoring
system is described in the following section.
The hypothesis that we consider in this study concerns
sequence data of n markers from a case–control sample
for association testing. The null hypothesis (H0) is that
there is no disease gene in the sequence of markers vs.
the alternative (H1) that there is a disease gene in the se-
quence. We propose to utilize p-values from single-
variant association tests to generate the single-variant
score at each individual marker along the sequence. Al-
though our method is not limited by the type of associ-
ation tests used to derive p-values, here we consider the
single-variant Cochran-Armitage trend chi-square test for
its robustness to the direction of the effect and departuresfrom Hardy-Weinberg equilibrium, ease of calculation
and wide applicability [37]. As a general version of the
maximal segmental scores for disease association studies
[35], we describe the GMSS method in the following four
sections. A potentially useful resource resulting from
this work is a freely available R code posted on the fol-
lowing website http://www.csjfann.ibms.sinica.edu.tw/
eag/programlist/GMSS/GMSS.html. No experimental
research is reported in this manuscript.
Calculating single-variant scores and partial sums
We propose a scoring system for converting the p-
value into a score at each marker in the sequence.
Given a sequence of p-values {p1,…,pn} each derived
from the Cochran-Armitage trend Chi-square test, the
single-variant score Yi at marker i is defined as Y i ¼ −2
ln pið Þ− χ21−α 4ð Þ−χ21−α 2ð Þ
 
, i = 1,…,n. The scoring system
is derived based on Fisher’s p-value combining method
[38].
The single-variant score sequence {Y1,…,Yn} is calcu-
lated by setting the alpha at a conventional level of 5%.
Thus, the equation for the single-variant scores becomes
Yi = −2ln(p1)-3.5, i = 1,…,n. In an attempt to locate a seg-
ment with disease association when scanning a marker
sequence, the reduction of 3.5 used in our scoring equa-
tion is considered as the token to pay when including an
adjoining marker. For a single marker, the threshold of
significance at 5% level would be χ20:95 2ð Þ ¼ 5:99 with
the degrees of freedom (df) of 2. When an additional marker
is considered, the df would become 4 and the threshold of
significance would be increased to χ20:95 4ð Þ ¼ 9:49 . Thus,
when including an adjoining marker, the threshold of signifi-
cance would be elevated by 3.5 (i.e. from 5.99 to 9.49), ac-
cording to Fisher’s method [38]. Based on this observation
that the threshold of significance would be elevated by 3.5,
we take this into account when calculating the scores by in-
cluding a payoff of 3.5. Our scoring equation is a combin-
ation of a chi-squared statistic and a payoff value of 3.5 for
converting p-values to continuous scores. Note that this is
the inherent level on a marker test based on Chi-squares for
constructing the empirical distribution of the null hypoth-
esis, not directly related to the level of significance for the
test on the region based on the general maximal segmental
score to be described later.
The single-variant scores {Y1,…,Yn} are then aggre-
gated in a sequential fashion to form a sequence of
partial sum scores {U0,U1…,Un} where U0 ¼ 0; Um ¼Xm
i¼1Y i; m ¼ 1; 2;…; n . U0 is the initial partial sum
score. Um is the partial sum up to the m
th marker in
the sequence. The partial sum scores Um as a func-
tion of the single-variant scores Yi are not monoton-
ically non-decreasing since the Yi’s can have negative
values.
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Given the partial sum score sequence {U0,U1…,Un},
the ladder points are defined as J0 ¼ 0; J v ¼ min
j
j : j≥Jv−1 þ 1; Uj−UJv−1 < 0
 
; ν ¼ 1; 2;… [32]. Figure 1
shows an example of the ladder points (solid dots) for
a sequence of 20 SNPs. Ladder points are where new
record lows of the partial sum scores occur as one
moves along the sequence marker by marker. As the
ladder points are identified along the sequence, regions
bounded by two adjacent ladder points form sub-
sequences. As shown in Figure 1, there are ten ladder
points which form ten sub-sequences. The ladder
points are the 1st to 4th, 13th, 15th to 18th, and 20th
SNPs with record low partial sums U1 to U4, U13, U15
to U18, and U20, respectively. Note that a ladder point
occurs only when the partial sum is lower than the par-
tial sum of the last ladder point.
The way to which we select the ladder points is moti-
vated by methods for matching amino acid sequences
based on similarity scores such as BLAST [32-34]. For
our disease association study, the purpose for the lad-
der points is to form sub-sequences along the input
marker sequence so that within each smaller region,
we can calculate the general segmental score in the
next section. By using the ladder points, it helps us to
find the region with the highest score which is likely to
be where disease association would be identified. This
also helps to reduce data dimensionality confronted by
high-throughput data.Figure 1 An example of partial sum scores for 20 SNPs. Ladder points
scores (open circles). U8 and U4 indicate the partial sum scores for the 8th
the difference between U8 and U4 which occurs in the sub-sequence bouCalculating general segmental scores and the general
maximal segmental score
For each sub-sequence, a general segmental score i.e., Sv
is calculated as the difference between the largest partial
sum within a sub-sequence and the initial partial sum
value of the sub-sequence. The equation used to obtain





; ν ¼ 1; 2;…:
The general segmental scores are non-negative values
defined as the uphill height within the sub-sequence
bounded by two adjacent ladder points. In the example
shown in Figure 1, the general segmental scores for the
ten sub-sequences are 0, 0, 0, 0, (U8-U4), (U14-U13), 0, 0,
0, (U19-U18), respectively. The zero score indicates no in-
crease in-between the two adjacent ladder points. The
larger the score is, the higher the likeliness for the exist-
ence of target SNPs to be within the segment.
The largest segmental score of the whole sequence is
identified as the general maximal segmental score GMSS =
max{S1,S2,…}. The GMSS is (U8-U4) in the example shown
in Figure 1. The significance of GMSS is evaluated via
permutation as shown below.
Permutation for empirical null distribution
To test the hypothesis of disease gene, the p-value of
GMSS is estimated by permutation. To derive the empir-
ical distribution of GMSS while preserving the structure
of the genotype data, we perform 1,000 replications by(solid dots) are the positions with record new lows of the partial sum
and 4th SNPs, respectively. The general maximal segmental score is
nded by the 4th and 13th SNPs.
Table 1 Minor allele frequency (MAF) distribution in a
1 MB region for the reference panel
MAF < 1% (1%, 2.4%) (2.4%, 5%) > 5%
Proportion (%) 40 10 10 40
There are 5086 SNPs and the reference panel is 379 EUR in TGP.
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scribed above each time. The observed GMSS is then
compared to the empirical distribution to derive the em-
pirical p-value which is defined as the proportion of per-
muted GMSS that are at least as extreme as the
observed one under the empirical distribution. Our re-
jection rule is to reject the null hypothesis if GMSS > c,
where P(GMSS > c|H0) = α and c is the threshold corre-
sponding to the level of significance α = 0.05 under the
null hypothesis H0.
Simulation studies
We conducted simulation studies by using HAPGEN2
[39] which generates case–control genotypes conditional
on a reference set of population haplotypes and an esti-
mate of the fine-scale recombination rate across the re-
gion. To consider more realistic set-ups, our simulation
was based on version 3 of the Phase 1 integrated data of
TGP released in March of 2012 [6]. We retained single
nucleotide polymorphisms (SNPs) in the reference panel of
379 Europeans (EUR) [40] from TGP for the simulation.
Using this reference dataset, we simulated case–control
data with and without the disease gene under different sce-
narios. Each of the scenarios was performed with 200 repli-
cations in our study with the following setups.
Simulation without disease gene
We chose a 1 MB region on chromosome (chr) 4 with
5086 SNPs and simulated data without the disease gene
for the sample size of 5000 cases and 5000 controls
[15,23,41].
Simulation with disease gene
We generated case–control data by considering four fac-
tors that may influence the performance on detecting
disease association, including (i) number of non-causal
variants, (ii) number of rare causal variants in the dis-
ease gene, (iii) relative risk of rare causal variants, and
(iv) combinations of rare and common causal variants in
the disease gene. We considered two different numbers
of non-causal variants (region sizes), two different num-
bers of rare causal variants and three different levels of
relative risks. In addition, we simulated two scenarios for
combinations of rare and common causal variants. In
total, we simulated 14 different scenarios involving a
mixture of rare and common causal variants.
For the number of non-causal variants, our simulation
considered two different region sizes, namely, 1 MB and
0.1 MB, which corresponded to 5086 and 524 non-causal
SNPs in TGP sequencing data. The smaller region i.e.,
0.1 MB was representative of a larger human protein cod-
ing gene based on recent data (mean size: 27 kb, range:
1 kb–2400 kb) [42]. We assumed that one disease gene wasembedded in the simulation region and the disease variants
were located near the center of the marker sequence.
To determine the number of rare and common SNPs
in the disease gene, we examined the distribution of rare
variants (MAF < 1%) based on 1174 genes of chr 4 in the
reference data. We found that the average proportion
and number of rare variants were 41% and 115, respect-
ively, which would correspond to a gene with 280 vari-
ants. Based on this observation, we simulated the disease
gene with similar numbers of total and rare variants i.e.,
one that contained 280 SNPs where 130 SNPs were rare
and the remaining 150 SNPs were common.
To investigate the effect of the number of rare causal
variants in the disease gene, our simulation assumed that
there were 50 and 70 rare causal variants. Re-sequencing
studies of the coding parts of the human genes had sug-
gested 50 disease variants to be a realistic level [15].
Some studies had assumed 50 rare causal variants in
their simulations [15,16] and others had considered a
range of 10% to 50% of rare variants to be causal [27,29].
Therefore, in our simulations, we considered scenarios
with 50 and 70 rare causal variants which corresponded
to about 38% and 54%, respectively, of the rare variants
in the disease gene being causal.
To study the effect of relative risks (rr), the rare causal
variants were assumed to have rr of 1.5, 1.7 and 2 [16].
The causal variants were arbitrarily chosen from the rare
variants in the disease gene and an additive disease
model was assumed. To study the impact of combina-
tions of both rare and common causal variants, we con-
sidered two simulation scenarios. The scenarios assumed
a combination of 50 rare causal variants with rr of 1.5
and one common causal variant with MAF of 10% and
rr of 1.1 and 1.2 [30,43].Performance evaluation
We compared GMSS to CMC [14] and WSS [15] by
examining the type I error rate and power in our simula-
tion. We also compared to SKAT by using the unified
approach with the option that improves the tail probability
i.e., SKAT-O [29]. The MAF threshold for rare variants
was 1% and default values were applied in the other pa-
rameters for CMC, WSS and SKAT-O for the analyses.
Significance was declared at the p-value cut-off of 0.05.
For type I error analysis, we applied GMSS, CMC,
WSS and SKAT-O to the simulation data without the
disease gene. The type I error rate was defined as the
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nificant in the simulation without the disease gene.
For the analysis on power, we applied all four methods
to the simulation data with disease gene. For CMC, WSS
and SKAT-O, power was defined as the proportion of rep-
licates which were declared significant in scenarios simu-
lated with the disease gene. For GMSS, the power was
defined as the proportion of replicates which yielded sig-
nificant p-values and correctly identified the region of the
true causal gene within the simulated marker sequence.
Results
Reference dataset
The reference dataset used in our simulation was from
TGP sequencing data of 379 Europeans. The MAF dis-
tribution of 5086 markers in a 1 MB region in this refer-
ence panel was shown in Table 1. When using 1% as the
MAF threshold for defining rare variants, our result
showed that there were about 40% rare variants and 60%
common variants in the reference data. The median and
mean MAFs were 2.4% and 10.3%, respectively, in this
dataset. The result on the MAF distribution based on all
markers on chr 4 for the reference panel was similar
(not shown). For the rare causal disease markers that
were chosen arbitrarily for the simulation, the median
MAF of the rare causal variants was 0.5% with the range
being from 0.4% to 0.92% in the reference panel.
Type I error
For type I error analysis, we applied GMSS, CMC, WSS and
SKAT-O to the simulation data with no disease gene. Table 2
showed the type I error rate over 200 replicates for these
four methods under the simulation scenario with no disease
gene in a 1 MB interval containing 5086 polymorphic SNPs
in TGP sequencing data for 5000 cases and 5000 controls.
The type I error rate was the lowest for GMSS (0.04)
followed by CMC (0.05), SKAT-O (0.06) and WSS (0.08).
The result indicated that all four methods had reasonably
well-controlled type I error rate in our simulation.
Power
For comparing the performance on the power for detecting
the disease gene, we applied GMSS, CMC, WSS and SKAT-
O to the simulation data with disease gene. Figure 2 showed
the results on power of these methods for the impact of
non-causal variants, rare causal variants and relative risk (rr).Table 2 Type I error rate under the simulation scenario of
no disease gene
Method GMSS CMC WSS SKAT-O
Type I error rate 0.04 0.05 0.08 0.06
Data were generated for 5000 cases and 5000 controls based on a 1 MB
region (5086 SNPs) of TGP sequencing data.In scenarios where there were 50 rare causal variants
in a sequence with 5086 non-causal variants (1 MB), the
power for detecting the disease gene increased for all
four methods as rr increased with the rank in power be-
ing GMSS > SKAT-O > WSS > CMC (Panel A). Excep-
tions were when rr was raised to 2, CMC had higher
power than WSS. For CMC, WSS and SKAT-O, the re-
sults on the significance for disease association were for
the overall region in the analysis while GMSS provided
not only the p-value but also the location of a finer re-
gion for the identified disease association. The results on
the regions identified by GMSS under these simulation
scenarios showed that the region with association found
by GMSS spanned the disease gene and an average of
27, 15 and 15 SNPs that were assumed non-causal when
rr was 1.5, 1.7 and 2, respectively. The same trend was
observed for the power with 70 rare causal variants
(Panel B). In these scenarios, the regions identified by
GMSS overlapped with the disease gene and an add-
itional 36, 35 and 34 non-causal SNPs on average for rr
of 1.5, 1.7 and 2, respectively.
When the number of non-causal variants was smaller
(i.e., 524 variants in 0.1 MB), the power for detecting the
disease gene was increased for all four methods across all
levels of rr in the scenarios with 50 rare causal variants
(Panel C). The rank in power was GMSS > SKAT-O >
CMC > WSS. The regions identified by GMSS spanned
the disease gene and an average of 9, 12 and 10 non-causal
SNPs for rr of 1.5, 1.7 and 2, respectively. Our results
showed the same trend in power when the number of rare
causal variants was increased to 70 (Panel D). In these sce-
narios, the regions identified by GMSS overlapped with the
disease gene and an additional 9, 9 and 10 non-causal
SNPs on average for rr of 1.5, 1.7 and 2, respectively.
For the impact of relative risk, the overall result showed
that there was an increasing trend in power as rr increased
for all methods. The average power was increased by 44%,
46%, 30% and 14% for CMC, WSS, SKAT-O and GMSS, re-
spectively, as the level of rr increased from 1.5 to 1.7 and 2.
For the impact of non-causal variants, there was an in-
creasing trend in power for all the methods when the num-
ber of non-causal variants decreased. There was an average
of 3.1-fold, 2.4-fold and less than 1-fold increase in power
for WSS, SKAT-O and GMSS, respectively as the number
of non-causal variants decreased from 5086 (1 MB) to 524
SNPs (0.1 MB). For CMC, there was a 10-fold increase in
the average power when the number of non-causal variants
decreased in the simulation.
For the impact of number of rare causal variants, the aver-
age increase in power going from 50 to 70 rare causal SNPs
was about 11%, 15%, 12% and 36% for CMC, WSS, SKAT-
O and GMSS, respectively, in the 1 MB scenarios. A similar
trend was also shown in the 0.1 MB settings. Although
both the number of rare causal variants and non-causal
A C
B D
Figure 2 Power for detecting the disease gene (280 SNPs) for 5000 cases and 5000 controls. A. 50 rare causal variants (MAF < 1%) in a 1 MB
(5086 non-causal SNPs) region of TGP sequencing data with relative risk (rr) of 1.5, 1.7 and 2. B. 70 rare causal variants (MAF < 1%) in a 1 MB (5086 non-
causal SNPs) region of TGP sequencing data with rr of 1.5, 1.7 and 2. C. 50 rare causal variants in a 0.1 MB (524 non-causal SNPs) region of TGP sequencing
data with rr of 1.5, 1.7 and 2. D. 70 rare causal variants in a 0.1 MB (524 non-causal SNPs) region of TGP sequencing data with rr of 1.5, 1.7 and 2.
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methods were more sensitive to one than the other. For
example, the results appeared to show that SKAT-O was
relatively less sensitive to the number of rare causal vari-
ants and GMSS was relatively less sensitive to the num-
ber of neutral markers in the sequence.
To study the effect of both rare and common causal
variants, we compared the power of CMC, WSS, SKAT-
O and GMSS in scenarios with combinations of these
variants. In the scenario that assumed 50 rare causal var-
iants with rr of 1.5 and one common causal variant with
MAF of about 10% and rr of 1.1 in a 1 MB interval of
TGP sequencing data, the power of GMSS for detect-
ing the disease gene was 0.52 and the identified regionoverlapped with the disease gene and an average of
117 additional non-causal SNPs. When the rr for the
common causal variant was raised to 1.2, the power of
GMSS was increased to 0.65 and the identified region
overlapped with the disease gene and an average of 23
additional non-causal SNPs. The results in the com-
bination scenarios for CMC, WSS and SKAT-O
showed almost no difference to that from the scenario
with 50 rare causal variants with rr of 1.5.
Application of GMSS - using Parkinson’s disease as a
model
To demonstrate the application of GMSS on real data, we
performed a real data analysis using a publically available
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Omni GWA Project, Accession: phs000196.v2.p1) [31,44].
The downloaded dataset contained IlluminaHumanOmni1-
Quad_v1-0_B GWAS data for 2000 individuals with Par-
kinson’s disease and 1986 control subjects [31]. To obtain
the single-variant score sequence, we performed Cochran-
Armitage trend chi-square test by using PLINK to obtain
the p-value at each individual SNP [45]. We followed the
steps as described in method to perform association ana-
lysis using GMSS as well as SKAT-O [29] and compared
the results with the current literature.
Parkinson’s disease has been one of the most common
neurodegenerative diseases affecting over 1% of the eld-
erly population [46]. Many studies have provided evi-
dence on the association between Parkinson’s disease
and the SNCA gene on chromosome 4 [31,46-49]. To
ensure that our method could at least identify the asso-
ciation of this gene, we analyzed all 59,377 SNPs on chr
4 to identify disease association. The result from our
analysis showed that there was a significant disease asso-
ciation in a region of 706.9 KB consisting of 155 SNPs
(Additional file 1) (p-value = 0.033). About 14% of the
SNPs in this region had MAFs below 1% which was similar
to the distribution observed when using all SNPs on chr 4
in this dataset. The identified region included the SNCA
locus which was a protein coding gene that may serve to
integrate presynaptic signalling and membrane trafficking
and had previously been implicated in the pathogenesis of
diseases such as Parkinson’s and Alzheimer’s diseases
[31,46-49].
In comparison, SKAT-O could not be directly applied
on the data due to the large number of markers. We
thus truncated the data by removing markers on both
ends and analyzed a sequence of a smaller set of markers
(30,000 SNPs) by using both GMSS and SKAT-O. Our re-
sults indicated that GMSS identified the same sub-region
for disease association as when the entire chromosome
was analyzed (p = 0.005). The result for SKAT-O based on
these 30,000 SNPs was also significant (p = 0.001) albeit
with no further indication on the corresponding region
for the association on chr 4. This analysis by GMSS took
about 10 minutes using a linux workstation with 2 GHz
CPU and 128G RAM while the analysis by SKAT-O took
more than 72 hours with the same computing power.
The hyaluronan synthase 2 (HAS2) gene on chr 8 was
not significant in the main sample or meta-analysis, but it
was marginally significant in a replication cohort [31].
Based on this, as well as independent evidence showing as-
sociation for this gene [50], we analyzed this region to see if
our method is capable of identifying the association in the
main sample. We performed the analysis by using GMSS
and compared our result with SKAT-O. The analysis by
GMSS identified a region of 22 SNPs (Additional file 1)
with significant disease association (p = 0.028). About 9% ofthe SNPs in this region had MAFs below 1% in this dataset.
The result by SKAT-O identified no significant association
for this gene (p = 0.56).
Recently, the WNT signaling pathway involving KRE-
MEN1 has been reported to be associated with the cell
replacement therapy for Parkinson’s disease [51]. Evidence
has indicated that knockdown of Kremen1 significantly
enhance axon outgrowh in murine dorsal root ganglion
neuronal culturals [52]. KREMEN1 has been shown to be a
negative regulator of the canonical WNTsignaling pathway
that is important for the healthy functioning of the adult
brain [53]. A potential role for this gene is in the regulation
of cellular responses upon extracellular stimulus or cell-
cell interaction in neuronal and/or muscle cells [54]. This
gene was previously reported to have an association with
schizophrenia [55]. To test the association between KRE-
MEN1 and Parkinson’s disease, we performed GMSS using
225 SNPs spanning 1 MB on chr 22. The result identified a
63.7 KB region of 25 SNPs (Additional file 1) with signifi-
cant disease association (p-value = 0.006). About 9% of
these SNPs were rare (MAFs below 1%). The association
was not identified when using SKAT-O (p = 0.2) and was
not reported in the original study [31].
Discussion
With growing marker density and amounts of rare vari-
ants available in sequencing data, statistical methods
have been developed to address the issue of missing her-
itability in identifying the causal variants for common
diseases. Due to the large number of small individual ef-
fect and low allele frequency of rare variants, traditional
single-variant tests have low power in detecting rare
variant association. It has been shown that rather than
analyzing rare variants individually, aggregating the vari-
ants together can help mitigate the problem.
In this study, we propose a GMSS method that utilizes
the aggregate scores from markers within a neighbor-
hood to identify the region most likely harbouring the
disease gene with rare and/or common causal variants.
We develop a scoring system that is a combination of a
chi-squared statistic and a payoff value following the
concept of Fisher’s p-value combining approach [38].
Our scoring system assigns continuous scores for individ-
ual markers based on single-variant association p-values.
The scores are aggregated sequentially and a region-
partitioning procedure identifies the sub-sequence that
has the strongest combined evidence for disease associ-
ation. Unlike region- or gene-based methods which re-
quire prior information on candidate regions, our method
is capable of identifying the segment with disease associ-
ation. For the methods that we have compared in this
study, they would require prior knowledge as to the region
or candidate gene to associate it with disease. This is be-
cause these methods provide an overall p-value for disease
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tions when the candidate region is not known or when an
entire chromosome is analyzed by these methods, their re-
sult would not be able to guide researchers to identify a
finer segment.
Our simulation is based on the TGP sequencing data
of the EUR reference panel in order to mimic realistic
minor allele frequencies and linkage disequilibrium spec-
tra [6,39,40]. We simulate case–control datasets under
different scenarios to evaluate the type I error rate and
power by comparing GMSS with CMC [14], WSS [15]
and SKAT-O [29]. The factors that are examined include
the number of non-causal variants, the number of rare
causal variants, relative risk and combinations of rare
and common causal variants. Under all the simulation
settings considered in this study, the results show that
GMSS has similar or better power with well-maintained
type I error rate as compared with the other methods.
Our results indicate that the number of rare causal
variants and level of relative risk have a positive effect
while the number of non-causal variants has a negative
effect on power for all these methods. While the
methods that we compare with in this study are affected
by these factors, some methods are relatively more sensi-
tive to one than another. For instance, CMC and WSS
are relatively more sensitive to number of non-causal
variants and relative risk in our simulations. Both CMC
and WSS pool the variants together for detecting rare
variant association. CMC pools variants under the MAF
threshold together but it loses power when the regions
are large due to the increased degrees of freedom for the
Hotelling’s T2 test. While results for this method might
be different when altering the pre-set MAF threshold,
GMSS requires no such threshold to be specified in ad-
vance. For WSS, the variants are weighted according to
their frequencies by allowing rare variants to contribute
more to the test statistic. These type of methods have an
advantage when all the variants that are rare are causal
and with the same direction effect on the disease trait,
scenarios unlikely to be observed with large-scale data
such as in sequencing based association studies. Our
method utilizes scores based on p-values for combining
the variants and thus is not affected by the direction of
the effect of the disease variants.
It has been suggested that methods that use sums of
single-variant statistics such as SKAT-O have better
power for detecting rare variant association as compared
with pooling tests [16]. As shown in our result, SKAT-O
has a better power than pooling tests in general. It is a
linear combination of pooling test and SKAT, which is a
multivariate technique using generalized linear models.
SKAT-O optimizes between pooling test and SKAT to
achieve more power. Although our result shows that the
change in power when increasing the number of rarecausal variants is not as substantial for SKAT-O as com-
pared with our method, the power is increased by a larger
amount than GMSS when the number of neutral variants
decreases in our simulation scenarios.
The performance in power for GMSS is better than
SKAT-O in the scenarios with smaller relative risk and
more neutral variants. In scenarios with smaller regions
and fewer neutral variants, the power for GMSS is simi-
lar to SKAT-O. Our simulation result shows that the
number of rare causal variants has a relatively larger im-
pact on GMSS than the other methods. When increasing
the number of rare causal variants, the increase in power
for GMSS is the greatest among these methods. When
there are many markers involved in the data such as in
sequencing based association studies, our results show
that GMSS is less sensitive to the inclusion of neutral
variants but relatively more sensitive to the number of
rare causal variants. In our study, we assume there are
50 and 70 rare causal variants since it has been sug-
gested to be a realistic number of disease variants in re-
sequencing studies of the coding regions of the human
genes [15,16]. We assume that one disease gene is em-
bedded in the simulation region and the disease variants
are located near the center of the marker sequence. One
of the limitations of the proposed method is that it is
sensitive to the clustering of disease variants and the
designed simulation studies. Further studies are required
to investigate situations with different clustering patterns
of the disease gene.
While the other methods only provide a p-value for
indicating whether somewhere along the sequence there is
disease association, GMSS is able to identify finer seg-
ments within the sequence that shows evidence for disease
association. Our results indicate that the segments identi-
fied by GMSS contain the disease gene plus around 9 to
117 additional non-causal variants on average. The region
identified by GMSS would not always be within the same
absolute size range. By using the simulation study, we aim
to show that this method was capable of identifying the
segment harbouring the underlying disease gene, a feature
that would be an advantage for exploratory analysis on
long sequence data in association studies.
One of the aims of this study is to identify the disease
susceptibility region in a long sequence of p-values. There-
fore, we use more stringent criteria for the power simula-
tions than for other tests that we compare with in this
study. Under the simulation scenario of a 1 MB region, the
results show that the proportion of significant wrong hits
ranges from 0.01 to 0.07; it is slightly higher when the num-
ber of causal variants and level of relative risk are lower.
Since it is likely that rare and common variants both
contribute to disease association in actual data, our simu-
lation also examine the scenarios with combinations of
both types of variants. The result shows that the power
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rare causal variants, suggesting that our method is able to
exploit the information from all variants. The power for
CMC, WSS and SKAT-O is almost the same as the sce-
narios without the common causal variant while the
power for GMSS is increased in the combination scenarios.
For pooling tests such as CMC and WSS, the effect of the
common causal variant seems to be diluted due to their
pooling and weighting schemes that favor rare variants.
Our simulation assumes 50 rare causal variants (rr = 1.5)
and one common causal variant with weak effect (rr = 1.1
and 1.2) in a 1 MB region. Possible reasons that the power
for SKAT-O remains similar could be that the number and
effect of the common causal variant might be too small
and it might require a much larger contribution to disease
association from both types of variants to overcome the
effect of neutral variants. Overall, when the effect and
number of common causal variant are small, GMSS does
not ignore this information. Under the scenario where both
common and rare variants contribute to the disease risk,
GMSS would be able to use information from both types
of variants thereby enhancing the power for identifying dis-
ease association. We also use the most recent development
of SKAT developed to deal with the combined effect of
both common and rare causal variants [30]. The results are
similar (not shown) to SKAT-O in the scenarios presented
in this study.
For GMSS, we analyze the scenario that has only the
common causal variant with rr of 1.1 by excluding the rare
causal variants. Excluding variants based on MAF thresh-
old has been a standard practice in traditional GWAS.
Under this scenario, the power for detecting the disease
gene is very low (power = 0.03) indicating that the inclu-
sion of both rare and common causal variants might yield
better power for identifying disease gene association. This
finding suggests that including rare variants in the analysis
might in part explain the missing heritability problem.
Our method deals with a sequence of p-values. For
sequencing data such as exomes, our method would not
be able to analyze the raw data. However, in a case–
control or family study design where p-values for each
individual variant is available, our method can be applied
to the p-value sequence for the markers in a region (e.g.
chromosome or gene) of interest to identify disease asso-
ciation. In addition, for whole genome or exome sequen-
cing data, the marker density is likely to be higher and
more variants may likely to be neutral. Our method has
the potential to accommodate such data because it is less
sensitive to the number of neutral variants than the other
methods being compared with in this study and imposes
no limit on the number of variants in the input sequence
of interest.
Under the setting of smaller sample sizes such as 500
cases and 500 controls, the performance for the methodsis worse than using larger sample sizes because rare vari-
ants would have been much harder to detect. As sug-
gested by previous studies [41], a well-powered RVAS
might aim for a discover sample of at least 15,000 cases
for 50% power and 25,000 cases for 90% power, together
with a substantial replication set given careful consider-
ation of possible factors such as mutation rate, etc.
Our method uses permutations to obtain the empirical
p-value. The permutation is carried out by shuffling the
case–control label for the purpose of generating the empir-
ical distribution for the general maximal segmental score
while preserving the structure of the genotype data. This
avoids distorting the structure of the genotype data so that
the empirical distribution is drawn from permutation data
with similar genotype structure to the original data. Under
the simulation for the null hypothesis where there is link-
age disequilibrium (LD) but no disease gene, the median
number of SNPs for permutation-based segments is 66
and that for the observed segments is 60. The Q1 and Q2
are 29 and 124 SNPs for permutation segments, respect-
ively. For the observed segments, the Q1 and Q2 are 26
and 139 SNPs, respectively. This result shows that the dis-
tribution of the permutation-based segments is similar to
the observed. It suggests that the permutations do not re-
sult in a different LD pattern. The problem with cryptic
population structure should be dealt with (such as using
genomic control) prior to an association analysis as it
indeed might produce false positive results.
For real data analysis, we use Parkinson’s disease case–
control data as a model to demonstrate the application
of GMSS. We confirm the association with SNCA and
further identify disease association with HAS2 and
KREMEN1. The permutation is not performed to cor-
rect for the number of comparisons. The p-values for
SNCA and HAS2 are border-line. However, our method
can be used as an alternative exploratory tool, not meant
to replace other disease gene association methods.
In this study, we are only interested in testing the associ-
ation between variants in a region, e.g., a chromosome or
gene, and disease status. It is possible to apply the pro-
posed method using genome-wide SNP data. There is no
limitation for our method on the study design (e.g. family-
based or case–control association studies) or the number
of variants in the input sequence. However, our method is
aimed to prioritize candidate regions and mitigate the
problem with multiple-comparisons. In GWAS, the pro-
portion of rare variants (<1%) is low. Applying our method
to such data is feasible, however, it would not show the
strength of our method which is designed to identify rare
variant association and can be applied to data with both
rare and common variants. For whole exome and whole
genome sequencing studies, our method can be applied to
a region (e.g. chromosome or gene) at a time and then
adjust for multiple comparisons by the user’s method of
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lysis [29].
The novelty of the current work is that we develop a
different scoring system to improve the power for identi-
fying rare-variant association. Our previous work is
based on the context of common variant association
[35,36] and its power for identifying rare variant associ-
ation would be poor. The score system in the previous
work uses discrete scores based on intervals of p-values.
For GMSS, we develop a different scoring system to in-
crease the power for identifying rare-variant association.
In this method, the scores are continuous and the score
system is a combination of chi-square statistic and a
payoff term. Different from our previous work, the
method proposed in this study aims to analyze data with
a higher marker density and larger proportion of rare
variants such as seen in TGP sequencing data. The sim-
ulations here are based on TGP data in order to mimic
the structure of a more recent actual data. The method
we propose in this study is to address the problems with
identifying rare variant association as well as in situa-
tions where both rare and common variants contribute
to disease risk.
Conclusions
GMSS is a platform independent method that is time effi-
cient and powerful for detecting rare variant association.
It is capable of using information from both rare and com-
mon causal variants and requires no threshold for MAF
or prior knowledge on candidate regions. GMSS is less
sensitive to the inclusion of a large proportion of neutral
variants and to the differences in direction of individual
variant effects. Unlike other methods, the result from
GMSS provides the p-value for disease association and a
finer region of the input marker sequence for the associ-
ation. Using Parkinson’s disease as a model, our method
not only confirms association for a known gene but also
identifies two genes previously found by other studies. In
spite of many existing methods, we conclude that our
method serves as an efficient alternative for exploring gen-
omic data containing both rare and common variants to
identify smaller regions within the data sequence most
likely to be associated with the disease.
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